ArticleInfection and drug resistance2025
Co-Production of KPC-2 and NDM-5 in a Carbapenem-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Molecular and phenotypic profiles of carbapenem- and third-generation cephalosporin-resistant Klebsiella pneumoniae isolates from the fecal microbiota of pediatric patients with COVID-19.BMC microbiology · 2026Article
- Emerging Cross-Resistance to Cefiderocol and Ceftazidime-Avibactam in KPC-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Epidemiological and genomic profiles of NDM-1-Producing ST25-KL2 carbapenem-resistant Klebsiella pneumoniae among pediatric patients in Hangzhou, China.BMC microbiology · 2026Article
- Combination Therapy with Ceftazidime-Avibactam, Aztreonam, and Topical Polymyxin B for NDM-ProducingInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: A multidrug-resistant CRKP strain, KP3T58, co-harboring Results: KP3T58 exhibited resistance to nearly all antibiotics except polymyxin. The strain's multidrug-resistant (MDR) phenotype resulted from a combination of chromosomal mutations and the multiple plasmid-borne resistance genes. Whole-genome analysis identified three key plasmids: a conjugative plasmid pKP3T58_1 (IncFIB/FII/R type, carrying a large resistance gene cluster); a conjugative plasmid pKP3T58_2 (IncI1-I type, high-frequency transfer, carrying Conclusion: This study demonstrates clonal evolution of ST11 CRKP to co-produce KPC-2 and NDM-5 within a host, clustering within a prevalent epidemic lineage. Critically, we provide experimental evidence that mobilizable plasmids retaining only a partial T4SS can undergo horizontal transfer when assisted by conjugative plasmids, fundamentally expanding our understanding of resistance dissemination. The convergence of high-risk epidemiology, MDR, and novel plasmid transfer mechanisms in strains like KP3T58 necessitates enhanced surveillance and urgent molecular investigation into the transmission dynamics of these threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.